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Purpose: Various strategies have been used to treat patients with nonpalpable prostate cancer (T1c). As
one of the treatments for this stage, a radical prostatectomy was performed and the outcomes were
evaluated.
Methods: Between 1993 and 2002, 117 patients with T1c received a radical prostatectomy and their
follow-up were examined by the end of 2013. Patients were classiﬁed according to risk groups using
prostate-speciﬁc antigen (PSA) and Gleasson score, and outcomes of respective groups were compared.
Results: Approximately 60% of patients were in low risk group, and the remaining patients were
grouped into the intermediate or high risks in half. In 22% insigniﬁcant cancer was detected. Biochemical
failure occurred in 14%. One patient exhibited bone metastasis, but no deaths from prostate cancer ware
observed. The ﬁve and ten year overall survival rates were 92% and 75%, respectively, and the biochemical
failure-free survival rates were 92% and 89%, respectively. No different outcomes were observed for the
different risk groups in the overall and biochemical failure-free survival rates. T1c tumors contain a
certain range of various stages of tumors, but most patients experienced favorable outcomes.
Conclusion: Radical prostatectomy as monotherapy is one of the treatment option for T1c prostate
cancer patients, who have a long life span and belong to intermediate or high risk groups.
© 2015 Published by Elsevier B.V. on behalf of Prostate International. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer is a serious disease in elderly males in Japan.
51,534 individuals were diagnosed with prostate cancer in 2008,
whereas 11,143 individuals died from prostate cancer in 2012.1
These rates have been increasing signiﬁcantly, which is due in
part to longer life spans and changes in nutrition and circum-
stances. Screening for prostate cancer in aged males is more
widespread, which has increased the detection of early stage
prostate cancer. Nonpalpable prostate cancer (T1c) accounts for a
considerable proportion of these cancers. T1c is managed using a
variety of treatment strategies, including surgical removal, radia-
tion, androgen deprivation and active surveillance. To evaluate the
effectiveness of radical prostatectomy for T1c patients, the presentuateSchool ofMedicine, Chiba
n.
imazaki).
ier B.V. on behalf of Prostate Intestudy was undertaken with long-term follow up after radical
prostatectomy.2. Materials and methods
Between 1993 and 2002, 134 cases of T1c cancer underwent
radical prostatectomy after consenting to treatment. Most patients
underwent further examination after screening. These cases were
conﬁrmed as N0M0 by whole body bone scan and computed to-
mography of the pelvic area. A complete record of the patient
outcomewas obtained for 117 of these cases by the end of 2013. The
present study evaluates these patients.
Prostate biopsy with 8e12 cores was performed via the perineal
route. Histological classiﬁcation was performed according to the
original Gleason classiﬁcation system.2 Radical retropubic prosta-
tectomy was performed with removal of the pelvic lymph nodes. In
the few cases with high risk cancer, adjuvant androgen deprivation
therapy was additionally performed. The prostate-speciﬁc antigen
(PSA [total PSA]) level was assayed using an Architect PSA kitrnational. This is an open access article under the CC BY-NC-ND license (http://
Table 2
Relationship between risk and pathological ﬁndings.
Risk pT2ab pT2c pT3 Total no. cases
Low 31 (45) 28 (38) 12 (17) 69
Intermediate 11 (44) 10 (40) 4 (16) 25
High 11 (48) 10 (43) 2 (9) 23
Invasion to the capsule is staged as pT3.
Number in parenthesis is the ratio to each risk group.
Table 3
Outcome of patients.
No. cases
Biochemical failure 16a (14)
Y. Amiya et al. / Prostate International 3 (2015) 27e3028(Abbott, Chiba, Japan). After surgery, the PSA level was assayed
every 3e6 months, and then every six months. Biochemical failure
was deﬁned as an increase of 0.2 ng/ml of PSA.
The risk of patients in stage T1c was separated according to the
PSAvalue and Gleason classiﬁcationwhichwere based on the NCCN
Guideline version 4. The cancer was staged according to the TNM
(2002) Guideline.
Survival was calculated with the KaplaneMeier method, and
differences among groups were assessed by the LogeRank test.
Statistical differences were determined by the unpaired two-group
t-test and p-value of0.05was considered statistical signiﬁcant. All
calculations were performed with SPSS statistical computer pro-
gram (IBM-SPSS Inc, Tokyo, Japan) and KaleidaGraph (Hulinks,
Tokyo, Japan).Clinical failure (bone) 1 (0.9)
Cause-speciﬁc death 0
Death of other causes 34 (29)
Malignancy 11
Pneumonia 6
Cerebral apoplexy 4
Cardiac disease 4
Others 9
Number in parenthesis is the ratio to whole patients (117
cases).
a Includes clinical failure case.3. Results
Approximately 60 of patients with T1c, whose PSA levels were
10 ng/ml and Gleason scores were6, were in the low risk group.
The remaining patients were separated into the intermediate or
high risk groups in half (Tables 1 and 2). Insigniﬁcant cancer, which
referred to 6 ng/ml of PSA and a tumor volume 0.5 cm3, was
observed in 22% of the tumors.
Formerly tumor invasion into the prostatic capsule was suspi-
cious to be the presence of tumor cells beyond capsule, and clas-
siﬁed in pT3. According to the TNM classiﬁcation scheme (2002),
capsular invasion was deﬁned as pT2. Almost all tumors in speci-
mens of pT3 patients in Table 2 placed touch or invasion into
capsule, Therefore, Group of pT3 was changed to pT2, tumors of
which located on capsule-line.
Biochemical failure occurred in 14% of all patients. Durations
between diagnosis and biochemical failure were 52 ± 40 months.
One patient in the high risk group experienced clinical failure and
was treated with combined androgen deprivation therapy (LHRH
plus bicalutamide). There was no relationship between the risk
groups and pathological tumor stages (Table 2). There were no
prostate cancer-speciﬁc deaths (Table 3).
The overall and biochemical failure-free survival rates are
shown in Figs. 1 and 2, respectively. The overall survival rates were
92% and 75%, whereas the biochemical failure-free survival rates
were 92 and 89% at ﬁve and ten years after surgery, respectively.
The average age of the patients was 68 ± 5.8 years at the time of
operation. According to the statistics of the Ministry of Health,
Labor and welfare Japan (2000), the average life term is 18.8 years
(65 years old) and 15.1 years (70 years old), therefore, surgery does
not seem to have an effect on life span. There were no signiﬁcant
differences in the overall and biochemical failure-free survival rates
of the different risk groups (Figs. 3 and 4). Despite thewide range ofTable 1
Patient characteristics.
No. cases
Age 60 yrs 14 (12)
61e70 66 (56)
71 37 (32)
PSA 10 ng/ml 73 (62)
11e20 27 (23)
21 15 (13)
Unknown 2 (2)
Gleason score 6 62 (53)
7 28 (24)
8 16 (14)
Unknown 11 (9)
Number in parenthesis is the ratio to respective item.the pathological extent associated with T1c, the postoperative
courses proceeded in a similar and favorable manner.4. Discussion
Nonpalpable prostate cancer, designated as T1c, includes a wide
range of stages.3 Operative specimens of T1c from the Johns Hop-
kins Hospital revealed the following tumors: 16% of insigniﬁcant
cancer, 10% of minimal extent cancer (organ-conﬁned, 0.2e0.5 cm3
of volume and <7 ng/ml of PSA), 37% of moderately extent cancer
(penetrated, >0.5 cm3 and >7 ng/ml of PSA) and 37% of advanced
cancer.4 Continuing to this report, the proportion of insigniﬁcant
cancer in operated T1c specimens exhibited 30.7%, whereas 19.6%
was advanced cancer.5 In other Institutes, the proportion of insig-
niﬁcant cancer in operated T1c specimens has been reported to
account for approximately 20e40 % of cases, including the presentFig. 1. Overall survival rate.
Fig. 2. Biochemical failure-free survival rate. Fig. 4. Biochemical failure-free survival rate for each risk groups: low (L), Intermediate
(I) and high (H). No differences between respective groups.
Y. Amiya et al. / Prostate International 3 (2015) 27e30 29study.6e8 In addition to insigniﬁcant cancer, T1c contains other
tumor types, most of which may be the localized cancers that are
included in the low risk group, however, approximately 17% of
these cases experienced biochemical relapse within eight years
after prostatectomy.9
Many factors have been used to discriminate among the
different types of T1c tumors. Moreover, patients with localized
cancer that has a mild growth tendency may be candidates for
active surveillance. Ultrasonography,10 the free-to-total PSA ratio
and PSA kinetics,11 biopsy ﬁndings and nuclear volume12 and
nomogram13,14 are used to distinguish tumor types in localized
cancers. The detection methods have been improved,15 but these
improvements do not guarantee a sharp distinction among the
tumor extent.16,17 One reason for this Inaccuracy in detection is the
tumor location. Nonpalpable tumors are predominantly located in
the anterior half of the gland at the apex to mid levels.18 Magnetic
resonance imaging detects tumors better than transrectalFig. 3. Overall survival rate for each risk groups: low (L). Intermediate (I) and high (H).
No differences between respective groups.ultrasound-guided biopsy, especially in an enlarged prostate.19
Some imaging modalities can be used to detect cancers with a
volume of <0.5 cm3.20 Using recent technologies, however, the
precise evaluation of nonpalpable prostate tumors remains to be
obtained until now.
Low risk patients had a 14% rate of biochemical failure at ﬁve
years under active surveillance,21 and a 78.6% of overall survival
rates at ten years.22 With respect to their outcomes after radical
prostatectomy, recent reports have shown a favorable prognosis for
T2a tumors inwhichmore than 85% and 80% of biochemical failure-
free survival rates at 10 years and 15 years, respectively.23e25
Whether tumor properties differ between T1c and T2 is an issue
for treatment. The biochemical failure-free, clinical progression-
free and overall survival rates were similar for patients in both
stages after radical prostatectomy.26 However, because of the
presence of invasion or high-grade prostatic intraepithelial
neoplasia, T2 is a more advanced tumor.27
The maximum tumor volume also inﬂuences on patient out-
comes: the biochemical failure-free survival rates of patients with a
tumor1.2 cm inmaximumdiameter showed a separation of 74.5%
and 99.0% at ﬁve years after surgery.28 Based on the probability of
biochemical failure, propose has been made that patients can be
divided in two groups using the following cut-off values: Gleason
score of 7, 10 ng/ml of PSA and a single core biopsy containing 50%
of cancer tissue. Using these parameters, the rate of freedom from
PSA relapse at ten years after the operation were 96% and 73% for
the low and high grades patients, respectively.29 Similarly, low risk
patients have been divided into low and very low-risk groups,
resulting in more accurate prognoses: the very low risk group
scarcely showed any biochemical failure.30
Conservative management for clinically localized prostate can-
cer was recommended in one study.31 However, in another study,
radical prostatectomy showed more beneﬁcial than watchful
waiting, especially for patients younger than 65 years of age.32 For
oldermen in the low risk group, non-curative approaches increased
the risk of prostate cancer-speciﬁc mortality.33 Radical prostatec-
tomy resulted in a better outcome than conservative treatments,
such as androgen-deprivation therapy.34 A delay in surgery by six
months or more results in a reduced progression-free survival rate
in low risk patients.35
Y. Amiya et al. / Prostate International 3 (2015) 27e3030Combining the afore-mentioned reports with the present study,
prostatectomy is one strategy for the treatment of T1c patients
irrespective of various risk groups. Although radical prostatectomy
has its limitations which occur in adverse effects, this treatment
option may result in a favorable outcome for localized prostate
cancer including T1c. Radical prostatectomy is an effective treat-
ment option for T1c prostate cancer patients who have an expected
long life span and belong to intermediate or high risk groups.
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